Merck KGaA is bowing out of the CAR-T development business, handing over its rights to Intrexon $XON in exchange for $150 million batch of stock.
The German Merck is characterizing the move as an R&D simplification process, staying focused where they believe they can make the most progress. And the deal comes three years after the two companies allied on CAR-T, with Intrexon contributing its tech — including Sleeping Beauty — for the preclinical work underway.
Merck KGaA is also investing $25 million in Intrexon, picking up a convertible note for stock in either Intrexon or its subsidiary Precigen.
Merck KGaA allied with Pfizer on the PD-L1 checkpoint Bavencio (avelumab), where they joined the first group of new therapies after Merck and Bristol-Myers Squibb pioneered the field. But the German Merck never made much of an impression in CAR-T, where Novartis and Kite — now owned by Gilead — are out front.
Much of the focus in this field has now turned to off-the-shelf CAR-T, where Allogene has been making its mark in early clinical work.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 50,900+ biopharma pros who read Endpoints News by email every day.Free Subscription